Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pharmacoeconomic Analysis of Fondaparinux Versus Enoxaparin for the Prevention of Thromboembolic Events in Orthopedic Surgery Patients

Pharmacoeconomic Analysis of Fondaparinux Versus Enoxaparin for the Prevention of Thromboembolic... Am J Cardiovasc Drugs 2004; 4 (5): 325-333 ORIGINAL RESEARCH ARTICLE 1175-3277/04/0005-0325/$31.00/0 © 2004 Adis Data Information BV. All rights reserved. Pharmacoeconomic Analysis of Fondaparinux Versus Enoxaparin for the Prevention of Thromboembolic Events in Orthopedic Surgery Patients 1 2 3 4 5 6 George Dranitsaris, Susan R. Kahn, Carmine Stumpo, Thomas W. Paton, Josee Martineau, Reginald Smith, Jeffrey S. Ginsberg on behalf of The Fondaparinux Canadian Health Economic Study Investigators 1 Augmentium Pharma Consulting, Toronto, Ontario, Canada 2 Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada 3 Toronto East General Hospital, Toronto, Ontario, Canada 4 Sunnybrook and Women’s College Health Sciences Centre, Toronto, Ontario, Canada 5 Cite de la Sant ´ e, Laval, Quebec, Canada ´ 6 Royal Jubilee Hospital, Victoria, British Columbia, Canada 7 McMaster University, Hamilton, Ontario, Canada Abstract Introduction: Fondaparinux is a novel synthetic antithrombotic that has been evaluated for the prevention of venous thromboembolism (VTE). In four large trials in patients who underwent major hip or knee surgery, fondaparinux was found to have a good safety profile and be more effective than enoxaparin. To generate Canadian pharmacoeconomic data for fondaparinux, an internationally developed cohort deterministic model was used to estimate the costs and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

Pharmacoeconomic Analysis of Fondaparinux Versus Enoxaparin for the Prevention of Thromboembolic Events in Orthopedic Surgery Patients

Loading next page...
 
/lp/springer-journals/pharmacoeconomic-analysis-of-fondaparinux-versus-enoxaparin-for-the-NCdGPKqaLh

References (20)

Publisher
Springer Journals
Copyright
Copyright © 2004 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-3277
eISSN
1179-187X
DOI
10.2165/00129784-200404050-00005
pmid
15449974
Publisher site
See Article on Publisher Site

Abstract

Am J Cardiovasc Drugs 2004; 4 (5): 325-333 ORIGINAL RESEARCH ARTICLE 1175-3277/04/0005-0325/$31.00/0 © 2004 Adis Data Information BV. All rights reserved. Pharmacoeconomic Analysis of Fondaparinux Versus Enoxaparin for the Prevention of Thromboembolic Events in Orthopedic Surgery Patients 1 2 3 4 5 6 George Dranitsaris, Susan R. Kahn, Carmine Stumpo, Thomas W. Paton, Josee Martineau, Reginald Smith, Jeffrey S. Ginsberg on behalf of The Fondaparinux Canadian Health Economic Study Investigators 1 Augmentium Pharma Consulting, Toronto, Ontario, Canada 2 Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada 3 Toronto East General Hospital, Toronto, Ontario, Canada 4 Sunnybrook and Women’s College Health Sciences Centre, Toronto, Ontario, Canada 5 Cite de la Sant ´ e, Laval, Quebec, Canada ´ 6 Royal Jubilee Hospital, Victoria, British Columbia, Canada 7 McMaster University, Hamilton, Ontario, Canada Abstract Introduction: Fondaparinux is a novel synthetic antithrombotic that has been evaluated for the prevention of venous thromboembolism (VTE). In four large trials in patients who underwent major hip or knee surgery, fondaparinux was found to have a good safety profile and be more effective than enoxaparin. To generate Canadian pharmacoeconomic data for fondaparinux, an internationally developed cohort deterministic model was used to estimate the costs and

Journal

American Journal of Cardiovascular DrugsSpringer Journals

Published: Aug 17, 2012

There are no references for this article.